ClinicalTrials.gg

Program

linerixibat

Also written as “Linerixibat”, “GSK2330672” and “GSK2330672 (linerixibat)”.

Its studies are mostly in Pruritus · Diabetes Mellitus, Type 2 · Liver Cirrhosis, Biliary · Cholestasis, led by GlaxoSmithKline.

Furthest: phase 3, since Nov 15, 201914 company-led studies, 2 open or runningNext primary completion: Oct 23, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline142 open or runningphase 3since Nov 15, 2019Jun 16, 2011Oct 23, 2028phase 3 · NCT07860710

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 16, 2011First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT01416324 · 17 enrolled · United States
  2. May 17, 2012Phase 1 study in Diabetes Mellitus, Type 2NCT01607385 · 56 enrolled · United States
  3. Jul 3, 2013Phase 2 study in Cholestasis, IntrahepaticNCT01899703 · 22 enrolled · United Kingdom
  4. Aug 22, 2013Phase 2 study in Diabetes Mellitus, Type 2NCT01929863 · 16 enrolled · United States
  5. Jul 24, 2014Phase 2 study in Diabetes Mellitus, Type 2NCT02202161 · 70 enrolled · United States
  6. Nov 15, 2016Phase 2 study in CholestasisNCT02966834 · 147 enrolled · United States, Australia, Canada and more
  7. Jun 18, 2019Phase 1 study in CholestasisNCT03992014 · 6 enrolled · United Kingdom
  8. Aug 8, 2019Phase 1 study in CholestasisNCT04053023 · 19 enrolled · United Kingdom
  9. Nov 15, 2019Phase 3 study in CholestasisNCT04167358 · 242 enrolled · United States, Argentina, Brazil and more
  10. Jun 25, 2021Phase 3 study in PruritusNCT04950127 · 238 enrolled · Germany, United Kingdom
  11. Nov 12, 2021Phase 1 study in PruritusNCT05133830 · 52 enrolled · United States
  12. May 23, 2022Phase 1 study in PruritusNCT05393076 · 8 enrolled · United States
  13. Jun 22, 2022Phase 1 study in PruritusNCT05435170 · 23 enrolled · United Kingdom
  14. Sep 30, 2026Phase 3 study in PruritusNCT07860710 · 40 planned

Ahead

  1. Oct 23, 2028Primary completion: phase 3 study in PruritusNCT07860710

TargetBeta

SLC10A2 →read by rule
“Ileal bile acid transporter inhibitor”ChEMBL 37, by rule

Other programs on SLC10A2

ProgramCompanyFurthest phaseStudies
maralixibatruleMirum Pharmaceuticalsphase 421

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07860710Pruritus3Not yet recruitingOct 23, 202840
NCT05435170Pruritus · United Kingdom1CompletedOct 10, 202223
NCT05393076Pruritus · United States1CompletedDec 6, 20228
NCT05133830Pruritus · United States1CompletedMay 31, 202252
NCT04950127Pruritus · Germany, United Kingdom3CompletedOct 28, 2024238
NCT04167358Cholestasis · United States, Argentina, Brazil and more3Active, not recruitingSep 30, 2026242
NCT04053023Cholestasis · United Kingdom1CompletedNov 25, 201919
NCT03992014Cholestasis · United Kingdom1CompletedAug 26, 20196
NCT02966834Cholestasis · United States, Australia, Canada and more2CompletedApr 15, 2020147
NCT02202161Diabetes Mellitus, Type 2 · United States2CompletedJan 30, 201570
NCT01929863Diabetes Mellitus, Type 2 · United States2CompletedNov 1, 201316
NCT01899703Cholestasis, Intrahepatic · United Kingdom2CompletedOct 7, 201522
NCT01607385Diabetes Mellitus, Type 2 · United States1CompletedDec 3, 201256
NCT01416324Diabetes Mellitus, Type 2 · United States1CompletedSep 9, 201117

How it is read

Names in the registry

  • “Linerixibat”, 5 entries
  • “GSK2330672”, 5 entries
  • “linerixibat”, 1 entry
  • “GSK2330672 (linerixibat)”, 1 entry
  • “Linerixibat tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.